ReviewCancers2023
Gastric Cancer with Peritoneal Metastases: Current Status and Prospects for Treatment.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Gastrointestinal CancerEmerging treatment modalities for gastric cancer with peritoneal metastases: a systematic review.The oncologist · 2025Pooled it
- The efficacy of non-complete omentectomy in the radical gastrectomy for gastric cancer: a meta-analysis and systematic review.Langenbeck's archives of surgery · 2025Pooled it
- Intraperitoneal delivery of the oncolytic virus CF17 improves tumor immunogenicity and survival in gastric cancer peritoneal metastasis.Molecular therapy. Oncology · 2026Article
- The Role of Diagnostic Laparoscopy in Staging and Treatment Planning of Gastric Cancer: A 400-Patient Retrospective Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
- Comparative Analysis of Lesion Detection and Uptake Characteristics ofJournal of gastrointestinal cancer · 2026Article
- LysoPS-GPR34 axis enhances tumor-associated macrophages efferocytosis to promote immune escape in gastric cancer peritoneal metastasis.Journal for immunotherapy of cancer · 2026Article
- Review
- Construction of a nomogram for preoperative prediction of occult peritoneal metastasis in advanced gastric cancer based on circulating tumor cells and fibrinogen to albumin ratio.Discover oncology · 2026Article
- Role of surgery in metastatic gastric cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Clinical risk factors associated with poor prognosis in gastric cancer patients with peritoneal metastasis.Medicine · 2026Article
- Prognostic stratification in gastric cancer with peritoneal metastasis: tumor biology and diagnostic modality as a surrogate for disease burden.BMC cancer · 2026Article
- Intraperitoneal immune microenvironment and efficacy of intraperitoneal chemotherapy in patients with gastric cancer and peritoneal metastasis.Scientific reports · 2025Article
- Pan-cancer clinicopathological and genomic characteristics of peritoneal metastasis.NPJ precision oncology · 2025Article
- Article
- Identification of molecular subtypes for breast cancer based on butyrate metabolism-related genes to assess prognosis and immune landscape.Translational cancer research · 2025Article
- IL33-ST2 axis is a predictive biomarker for anti-PD1 therapeutic efficacy in advanced gastric cancer.Journal of translational medicine · 2025Article
- Article
- Review
- Evaluating the Long-Term Impact of Cytoreductive Surgery for Gastric Cancer with Peritoneal Metastasis: Are We on the Right Path?Journal of personalized medicine · 2025Article
- Unaccounted clinical factors in CINV outcomes: the missing role of IO therapy, metastatic sites, and prophylaxis strategy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) has a poor prognostic and only one in four patients will have survived by 5 years after diagnosis. These poor results are due to the fact that most patients are diagnosed in advanced stages; peritoneal metastases (PM) are especially frequent and are difficult to treat. Currently, PM are considered a terminal stage of GC with a poor survival rate and are treated with palliative systemic chemotherapy. Since the beginning of the century, the treatment of PM from different origins has evolved; cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have become the treatment of choice for many malignant diseases that affect the peritoneum. CRS and HIPEC have also been used for patients with GC and PM, achieving survival results that have never been achieved when using systemic chemotherapy alone. The use of HIPEC can even prevent the development of peritoneal recurrences in patients with locally advanced GC as adjuvant therapy, can reduce the volume of peritoneal disease as neoadjuvant therapy, and can control symptoms in a palliative setting. The aim of this review is to collate the current scientific evidence regarding the treatment of PM of GC origin with surgery and intraperitoneal chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.